Compare Philip Morris International Inc. (PM) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs Smith & Nephew plc — how do they compare? Philip Morris International Inc. trades at $195 (market cap $293.07B), while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Philip Morris International Inc. is far larger — about 23.1× Smith & Nephew plc's market cap, and Philip Morris International Inc. pays the higher dividend (3.13%). Which is the better fit depends on your goals.
| PM | SNN | |
|---|---|---|
Market Cap | $293.07B | $12.71B |
Sector | Consumer Staples | Health |
52-Week High | $192.98 | $38.70 |
52-Week Low | $144.33 | $28.73 |
Enterprise Value | $339.57B | $15.48B |
Dividend Yield | 3.13% | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $192.72, down 0.13% on the day, with strong analyst support (17 buy ratings) and a $194 consensus price target. The stock shows bullish technical momentum above key support levels, while fundamentals reveal robust profitability with 26.74% net margins and consistent revenue growth to $40.65B in 2025. Recent news includes a profit forecast revision due to a $500M impairment charge and CFO succession planning.
PM offers stable dividend income and brand strength but faces headwinds from cost pressures and illicit market growth. The stock trades at a premium valuation (P/E 27.13) with elevated debt levels, requiring monitoring of pricing power and regulatory developments. Near-term catalysts include Q2 earnings and execution of the smoke-free transition strategy.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
